Search Results

There are 82331 results for: content related to: Fitting E max models to clinical trial dose–response data

  1. Effects of unstratified and centre-stratified randomization in multi-centre clinical trials

    Pharmaceutical Statistics

    Volume 10, Issue 1, January/February 2011, Pages: 50–59, Vladimir V. Anisimov

    Article first published online : 28 JAN 2010, DOI: 10.1002/pst.412

  2. An alternative phase II/III design for continuous endpoints

    Pharmaceutical Statistics

    Volume 10, Issue 2, March/April 2011, Pages: 105–114, Wong-Shian Huang, Jen-pei Liu and Chin-Fu Hsiao

    Article first published online : 22 FEB 2010, DOI: 10.1002/pst.418

  3. An optimal adaptive design to address local regulations in global clinical trials

    Pharmaceutical Statistics

    Volume 9, Issue 3, July/September 2010, Pages: 179–189, Xiaolong Luo, Weichung Joe Shih, S. Peter Ouyang and Robert J. DeLap

    Article first published online : 22 SEP 2010, DOI: 10.1002/pst.456

  4. Assessing departure from dose linearity under a repeated measures incomplete block design

    Pharmaceutical Statistics

    Volume 10, Issue 4, July/August 2011, Pages: 357–362, Bin Cheng and Shein-Chung Chow

    Article first published online : 22 NOV 2010, DOI: 10.1002/pst.474

  5. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints

    Pharmaceutical Statistics

    Volume 10, Issue 4, July/August 2011, Pages: 347–356, Martin Jenkins, Andrew Stone and Christopher Jennison

    Article first published online : 8 DEC 2010, DOI: 10.1002/pst.472

  6. Block response-adaptive randomization in clinical trials with binary endpoints

    Pharmaceutical Statistics

    Volume 10, Issue 4, July/August 2011, Pages: 341–346, Dominic Magirr

    Article first published online : 9 NOV 2010, DOI: 10.1002/pst.471

  7. Adapting by calibration the sample size of a phase III trial on the basis of phase II data

    Pharmaceutical Statistics

    Volume 10, Issue 2, March/April 2011, Pages: 89–95, Daniele De Martini

    Article first published online : 8 FEB 2010, DOI: 10.1002/pst.410

  8. Sample-size calculations for multi-group comparison in population pharmacokinetic experiments

    Pharmaceutical Statistics

    Volume 9, Issue 4, October/December 2010, Pages: 255–268, Kayode Ogungbenro and Leon Aarons

    Article first published online : 27 AUG 2009, DOI: 10.1002/pst.388

  9. Testing non-inferiority and superiority for two endpoints for several treatments with a control

    Pharmaceutical Statistics

    Volume 10, Issue 4, July/August 2011, Pages: 318–324, John Lawrence

    Article first published online : 14 OCT 2010, DOI: 10.1002/pst.468

  10. A flexible class of models for data arising from a ‘thorough QT/QTc study’

    Pharmaceutical Statistics

    Volume 10, Issue 2, March/April 2011, Pages: 122–127, Suraj P. Anand and Sujit K. Ghosh

    Article first published online : 22 MAR 2010, DOI: 10.1002/pst.420

  11. Investigating the assumption of homogeneity of treatment effects in clinical studies with application to meta-analysis

    Pharmaceutical Statistics

    Volume 11, Issue 1, January/February 2012, Pages: 49–56, Steven A. Julious and Anne Whitehead

    Article first published online : 2 DEC 2011, DOI: 10.1002/pst.494

  12. Assessing non-inferiority to an aggregate response with an application to development of pneumococcal conjugate vaccines

    Pharmaceutical Statistics

    Volume 10, Issue 4, July/August 2011, Pages: 332–340, Yi Pan, Guanghan F. Liu and Michael J. Dallas

    Article first published online : 9 NOV 2010, DOI: 10.1002/pst.470

  13. A note on dealing with missing standard errors in meta-analyses of continuous outcome measures in WinBUGS

    Pharmaceutical Statistics

    Volume 10, Issue 4, July/August 2011, Pages: 374–378, John W. Stevens

    Article first published online : 11 MAR 2011, DOI: 10.1002/pst.491

  14. Large sample inference for an assay quality measure used in high-throughput screening

    Pharmaceutical Statistics

    Volume 10, Issue 3, May/June 2011, Pages: 227–231, Antara Majumdar and David Stock

    Article first published online : 8 OCT 2010, DOI: 10.1002/pst.452

  15. Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim

    Pharmaceutical Statistics

    Volume 10, Issue 2, March/April 2011, Pages: 96–104, Martin Posch, Willi Maurer and Frank Bretz

    Article first published online : 6 APR 2010, DOI: 10.1002/pst.413

  16. Graphical displays for clarifying how allocation ratio affects total sample size for the two sample logrank test

    Pharmaceutical Statistics

    Volume 10, Issue 1, January/February 2011, Pages: 40–44, Benjamin R. Saville, Yong S. Kim and Gary G. Koch

    Article first published online : 14 JAN 2010, DOI: 10.1002/pst.407

  17. Sample size and proportion of Japanese patients in multi-regional trials

    Pharmaceutical Statistics

    Volume 9, Issue 3, July/September 2010, Pages: 207–216, Kimitoshi Ikeda and Frank Bretz

    Article first published online : 22 SEP 2010, DOI: 10.1002/pst.455

  18. Estimation of the limit of detection for quantal response bioassays

    Pharmaceutical Statistics

    Volume 10, Issue 3, May/June 2011, Pages: 203–212, Edwin van den Heuvel

    Article first published online : 4 MAY 2010, DOI: 10.1002/pst.435

  19. Increasing the sample size at interim for a two-sample experiment without Type I error inflation

    Pharmaceutical Statistics

    Volume 9, Issue 4, October/December 2010, Pages: 280–287, Keith Dunnigan and Dennis W. King

    Article first published online : 17 SEP 2009, DOI: 10.1002/pst.390

  20. Sample size re-estimation for survival data in clinical trials with an adaptive design

    Pharmaceutical Statistics

    Volume 10, Issue 4, July/August 2011, Pages: 325–331, Kanae Togo and Manabu Iwasaki

    Article first published online : 28 OCT 2010, DOI: 10.1002/pst.469